|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Eli Lilly and Company |
| Information provided by: | Eli Lilly and Company |
| ClinicalTrials.gov Identifier: | NCT00666718 |
Purpose
This study is designed to look at if a basal bolus regimen of insulin lispro protamine suspension provides the same glycemic control as a basal bolus regimen of insulin glargine (when one basal bolus regimen is injected once daily together with insulin lispro injected 2-3 times daily).
| Condition | Intervention | Phase |
|
Diabetes Mellitus, Type 2 |
Drug: Insulin Glargine Drug: Insulin Lispro Protamine Suspension |
Phase III |
| MedlinePlus related topics: | Diabetes |
| ChemIDplus related topics: | Insulin Insulin glargine Dextrose Insulin lispro Protamine |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
| Official Title: | A Prospective Randomized Trial to Compare Basal Bolus Therapies That Use Either Insulin Lispro Protamine Suspension or Insulin Glargine Together With Lispro Insulin in Patients With Type 2 Diabetes |
| Estimated Enrollment: | 380 |
| Study Start Date: | April 2008 |
| Estimated Study Completion Date: | October 2009 |
| Estimated Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|
1: Active Comparator
Glargine plus Insulin Lispro (2-3 injections) plus metformin
|
Drug: Insulin Glargine
patient glucose-level dependent, injection, once daily in the evening, 24 weeks
|
|
2: Experimental
Insulin Lispro Protamine Suspension plus Insulin Lispro (2-3 injections) plus metformin
|
Drug: Insulin Lispro Protamine Suspension
patient glucose-level dependent, injection, once daily in the evening, 24 weeks
|
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or | 1-317-615-4559 |
![]() |
Show 43 Study Locations |
| Eli Lilly and Company |
| Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
More Information
Lilly Clinical Trial Registry 
  |
| Responsible Party: | Eli Lilly ( Chief Medical Officer ) |
| Study ID Numbers: | 12047, F3Z-EW-IOPJ |
| First Received: | April 23, 2008 |
| Last Updated: | July 11, 2008 |
| ClinicalTrials.gov Identifier: | NCT00666718 |
| Health Authority: | Greece: Ethics Committee; Greece: National Organization of Medicines; Turkey: Ministry of Health; Czech Republic: Ethics Committee; Czech Republic: State Institute for Drug Control; Belgium: Federal Agency for Medicinal Products and Health Products; Belgium: Institutional Review Board; Germany: Federal Institute for Drugs and Medical Devices; United Kingdom: Medicines and Healthcare Products Regulatory Agency; United Kingdom: Research Ethics Committee; Romania: National Medicines Agency; Poland: Ministry of Health; Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products; Italy: Ethics Committee; Italy: Ministry of Health |
|
|
|
|